My Top Biotech Stocks to Buy in the Market Crash
Individual investors might be tempted to chase vaccines for SARS-CoV-2 or treatments for COVID-19, but it's still way too early to know which companies will succeed in their efforts. There will likely (hopefully) be multiple vaccines and treatments approved for use in the next two years, and established companies with track records of successful drug development and commercialization -- such as Johnson & Johnson and Sanofi -- are likely the best bets.
But the rest of the biopharma industry didn't vanish because of the coronavirus pandemic. While clinical trials will likely be delayed across the industry as a result of the current situation, all of the most promising long-term investing opportunities that existed in late February still exist today. Considering the stock market tumbled over 12% in March (and more pain is likely on the way), there are many opportunities in the biopharma sector for investors with a long-term mindset.
Here's why Fate Therapeutics (NASDAQ: FATE) and Iovance Biotherapeutics (NASDAQ: IOVA) are two pharma stocks to buy in the current investing environment.
Source Fool.com
